For the year ending 2025-12-31, RGNX had -$23,060K decrease in cash & cash equivalents over the period. -$126,377K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -193,878 |
| Stock-based compensation expense | 34,563 |
| Depreciation and amortization | 15,615 |
| Net accretion of discounts on marketable debt securities | 5,479 |
| Net realized gain on investments | 62 |
| Non-cash interest expense | 12,901 |
| Other non-cash adjustments | -597 |
| Accounts receivable | 7,661 |
| Prepaid expenses | 2,860 |
| Other current assets | -658 |
| Operating lease right-of-use assets | -6,653 |
| Other assets | 613 |
| Accounts payable | -2,284 |
| Accrued expenses and other current liabilities | 229 |
| Deferred revenue | 29,280 |
| Operating lease liabilities | -8,625 |
| Other liabilities | -2,997 |
| Net cash used in operating activities | -123,963 |
| Purchases of marketable debt securities | 332,630 |
| Maturities of marketable debt securities | 319,114 |
| Sales of equity securities | 62 |
| Purchases of property and equipment | 2,414 |
| Net cash provided by (used in) investing activities | -15,868 |
| Proceeds from exercise of stock options | 318 |
| Taxes paid related to net settlement of stock-based awards | 633 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,048 |
| Expenses related to at-the-market offering programs | 357 |
| Proceeds from issuance of royalty bond and warrants, net of transaction costs | 144,493 |
| Repayments under royalty monetization liabilities, net of interest | 28,098 |
| Net cash provided by financing activities | 116,771 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -23,060 |
| Beginning of period | 59,556 |
| End of period | 36,496 |
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)